| Market Cap | 5.45M | P/E | - | EPS this Y | 74.30% | Ern Qtrly Grth | - |
| Income | -10.59M | Forward P/E | -0.69 | EPS next Y | 32.20% | 50D Avg Chg | -23.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -1.00% |
| Dividend | N/A | Price/Book | 0.52 | EPS next 5Y | - | 52W High Chg | -79.00% |
| Recommedations | 2.00 | Quick Ratio | 5.89 | Shares Outstanding | 8.92M | 52W Low Chg | 102.00% |
| Insider Own | 2.42% | ROA | -80.50% | Shares Float | 8.85M | Beta | 0.50 |
| Inst Own | 5.67% | ROE | -206.10% | Shares Shorted/Prior | 204.65K/469.10K | Price | 2.62 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 3,625,088 | Target Price | 8.32 |
| Oper. Margin | - | Earnings Date | Nov 11 | Volume | 33,973 | Change | -1.50% |
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
| HC Wainwright & Co. | Buy | Jan 30, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PASQUALONE FRANK | Director Director | Sep 15 | Buy | 2.14 | 1,000 | 2,140 | 1,000 | 09/19/23 |